Predictive markers of radiotherapy-induced rectal cancer regression

Journal of Clinical Pathology

Volumn 67, Issue 10, 2014, Pages 859-864

  Shin, J S ^a   Tut, T G ^a   Ho, V ^a,b   Lee, C S ^a  

^a UNIVERSITY OF WESTERN SYDNEY   (Australia)

^b Molecular Medicine Research Group   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; TUMOR MARKER;

CANCER CELL; CANCER CONTROL; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; COLORECTAL CANCER; DNA DAMAGE; DNA END JOINING REPAIR; HISTOPATHOLOGY; HUMAN; HYPOXIA; IMMUNOHISTOCHEMISTRY; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; PATHOGENESIS; PREOPERATIVE RADIOTHERAPY; QUALITY OF LIFE; RADIATION INJURY; RADIOSENSITIVITY; RECTUM CANCER; REVIEW; TISSUE OXYGENATION; TREATMENT RESPONSE; METABOLISM; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROGNOSIS; RECTAL NEOPLASMS; TUMOR RECURRENCE;

COMBINED MODALITY THERAPY; HUMANS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RECTAL NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84907246957     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2014-202494     Document Type: Review

References (77)

1. Australian Institute of Health and Welfare (AIHW). Australian cancer incidence and mortality books. Canberra, ACT: AIHW, 2010.
2. Wolpin BM, Meyerhardt JA, Mamon HJ, et al. Adjuvant treatment of colorectal cancer. CA Cancer J Clin 2007;57:168-85.
3. Marijnen C, Kapiteijn E, Van de Velde C, et al. Acute side effects and complications after short-term preoperative radiotherapy combined with total mesorectal excision in primary rectal cancer: report of a multicenter randomized trial. J Clin Oncol 2002;20:817-25.
4. Peeters K, Van de Velde C, Leer J, et al. Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients-a Dutch colorectal cancer group study. J Clin Oncol 2005;23:6199-206.
5. Marijnen C, van de Velde C, Putter H, et al. Impact of short-term preoperative radiotherapy on health-related quality of life and sexual functioning in primary rectal cancer: report of a multicenter randomized trial. J Clin Oncol 2005;23: 1847-58.
6. O'Gorman C, Denieffe S, Gooney M. Literature review: preoperative radiotherapy and rectal cancer-impact on acute symptom presentation and quality of life. J Clin Nurs 2014;23:333-51.
7. Colorectal Cancer Collaborative Group. Adjuvant radiotherapy for rectal cancer: a systematic overview of 8,507 patients from 22 randomised trials. Lancet 2001;358:1291-304.
8. Glimelius B, Gronberg H, Jarhult J, et al. A systematic overview of radiation therapy effects in rectal cancer. Acta Oncol 2003;42:476-92.
9. Ortholan C, Francois E, Thomas O, et al. Role of radiotherapy with surgery for T3 and resectable T4 rectal cancer: evidence from randomized trials. Dis Col Rect 2006;49:302-10.
10. Folkesson J, Birgisson H, Pahlman L, et al. Swedish rectal cancer trial: long lasting benefits from radiotherapy on survival and local recurrence rate. J Clin Oncol 2005;23:5644-50.
11. Peeters KCMJ, Marijnen CAM, Nagtegaal ID, et al. The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg 2007;246:693-701.
12. Edge SB, Byrd DR, Compton CC, et al. eds. AJCC cancer staging manual. New York, NY: Springer-Verlag, 2010:143-64.
13. Berger C, de Muret A, Garaud P, et al. Preoperative radiotherapy (RT) for rectal cancer: predictive factors of tumor downstaging and residual tumor cell density (RTCD): prognostic implications. Int J Radiat Oncol Biol Phys 1997;37:619-27.
14. Wheeler JMD, Warren BF, Mortensen NJM, et al. Quantification of histologic regression of rectal cancer after irradiation: a proposal for a modified staging system. Dis Col Rect 2002;45:1051-6.
15. Ryan R, Gibbons D, Hyland JMP, et al. Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Histopathology 2005;47:141-6.
16. Spitz FR, Giacco GG, Hess K, et al. p53 immunohistochemical staining predicts residual disease after chemoradiation in patients with high-risk rectal cancer. Clin Cancer Res 1997;3:1685-90.
17. Dworak O, Keilholz L, Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorect Dis 1997;12:19-23.
18. Mandard A-M, Dalibard F, Mandard J-C, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 1994;73:2680-6.
19. Bouzourene H, Bosman FT, Seelentag W, et al. Importance of tumor regression assessment in predicting the outcome in patients with locally advanced rectal carcinoma who are treated with preoperative radiotherapy. Cancer 2002;94:1121-30.
20. Morgan MJ, Koorey DJ, Painter D, et al. Histological tumour response to pre-operative combined modality therapy in locally advanced rectal cancer. Colorect Dis 2002;4:177-83.
21. Shin J-S, Jalaludin B, Solomon M, et al. Histopathological regression grading versus staging of rectal cancer following radiotherapy. Pathology 2011;43:24-30.
22. Santos MD, Silva C, Rocha A, et al. Prognostic value of Mandard and Dworak tumor regression grading in rectal cancer: study of a single tertiary center. ISRN Surg. Published Online First: 4 March 2014. doi: 10.1155/2014/310542
23. Losi L, Luppi G, Gavioli M, et al. Prognostic value of Dworak grade of regression (GR) in patients with rectal carcinoma treated with preoperative radiochemotherapy. Int J Colorect Dis 2006;21:645-51.
24. Rodel C, Martus P, Papadoupolos T, et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 2005;23:8688-96.
25. Vecchio FM, Valentini V, Minsky BD, et al. The relationship of pathologic tumor regression grade (TRG) and outcomes after preoperative therapy in rectal cancer. Int J Radiat Oncol Biol Phys 2005;62:752-60.
26. Rosenberg R, Nekarda H, Zimmermann F, et al. Histopathological response after preoperative radiochemotherapy in rectal carcinoma is associated with improved overall survival. J SurgOncol 2008;97:8-13.
27. Ng W-L, Huang Q, Liu X, et al. Molecular mechanisms involved in tumor repopulation after radiotherapy. Transl Cancer Res 2013;2:442-8.
28. Dewhirst MW, Cao Y, Moeller B. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nature Rev Cancer 2008;8:425-37.
29. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nature Rev Cancer 2009;9:550-62.
30. Zhong H, Chiles K, Feldser D, et al. Modulation of hypoxia-inducible factor 1α expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/ FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 2000;60:1541-5.
31. Kilic-Eren M, Boylu T, Tabor V. Targeting PI3K/Akt represses hypoxia inducible factor-1alpha activation and sensitizes Rhabdomyosarcoma and Ewing's sarcoma cells for apoptosis. Cancer Cell Int 2013;13:36.
32. Zhou B-BS, Elledge SJ. The DNA damage response: putting checkpoints in perspective. Nature 2000;408:433-39.
33. Shiloh Y. The ATM-mediated DNA-damage response: taking shape. Trends Biochem Sci 2006;31:402-10.
34. D'Amours D, Jackson SP. The MRE11 complex: at the crossroads of DNA repair and checkpoint signalling. Nat Rev Mol Cell Biol 2002;3:317-27.
35. Durocher D, Jackson S. DNA-PK, ATM and ATR as sensors of DNA damage: variations on a theme? Curr Opin Cell Biol 2001;13:225-31.
36. Lobrich M, Jeggo PA. The impact of a negligent G2/M checkpoint on genomic instability and cancer induction. Nature Rev Cancer 2007;7:861-9.
37. van Gent DC, van der Burg M. Non-homologous end-joining, a sticky affair. Oncogene 2007;26:7731-40.
38. Habraken Y, Jolois O, Piette J. Differential involvement of the hMRE11/hRAD50/ NBS1 complex, BRCA1 and MLH1 in NF-[kappa]B activation by camptothecin and X-ray. Oncogene 2003;22:6090-9.
39. Janssens S, Tschopp J. Signals from within: the DNA-damage-induced NF-κB response. Cell Death Diff 2006;13:773-84.
40. Zha S, Boboila C, Alt FW. Mre11: roles in DNA repair beyond homologous recombination. Nat Struct Mol Biol 2009;16:798-800.
41. Stewart GS, Maser RS, Stankovic T, et al. The DNA double-strand break repair gene hMRE11 is mutated in individuals with an ataxia-telangiectasia-like disorder. Cell 1999;99:577-87.
42. Söderlund K, Stål O, Skoog L, et al. Intact Mre11/Rad50/Nbs1 complex predicts good response to radiotherapy in early breast cancer. Int J RadiatOncol Biol Phys 2007;68:50-8.
43. Choudhury A, Nelson LD, Teo MT, et al. MRE11 expression is predictive of cause-specific survival following radical radiotherapy for muscle-invasive bladder cancer. Cancer Res 2010;70:7017-26.
44. McKinnon PJ. ATM and ataxia telangiectasia. EMBO reports 2004;5:772-6.
45. Kim W-j, Vo QN, Shrivastav M, et al. Aberrant methylation of the ATM promoter correlates with increased radiosensitivity in a human colorectal tumor cell line. Oncogene 2002;21:3864-71.
46. Sun X, Becker-Catania SG, Chun HH, et al. Early diagnosis of ataxia-telangiectasia using radiosensitivity testing. J Pediat 2002;140:724-31.
47. Lin C, Yu Y, Zhao H-g, et al. Combination of quercetin with radiotherapy enhances tumor radiosensitivity in vitro and in vivo. Radiother Oncol 2012;104:395-400.
48. Grabsch H, Barker L, Maughan N, et al. Expression of DNA double-strand break repair proteins ATM and BRCA1 predicts survival in colorectal cancer. Clin Cancer Res 2006;12:1494-500.
49. Negroni D, Stronati L, Grollino M, et al. Radioresistance in a tumour cell line correlates with radiation inducible Ku 70/80 end-binding activity. Int J Radiat Biol 2008;84:265-76.
50. Zlobec I, Steele R, Nigam N, et al. A predictive model of rectal tumor response to preoperative radiotherapy using classification and regression tree methods. Clin Cancer Res 2005;11:5440-3.
51. Rodel F, Frey B, Leitmann W, et al. Survivin antisense oligonucleotides effectively radiosensitize colorecdtal cancer cells in both tissue culture and murine xenograft models. Int J Radiat Oncol Biol Phys 2008;71:247-55.
52. Moding EJ, Kastan MB, Kirsch DG. Strategies for optimizing the response of cancer and normal tissues to radiation. Nat Rev Drug Discov 2013;12:526-42.
53. Nesslinger NJ, Sahota RA, Stone B, et al. Standard treatments induce antigen-specific immune responses in prostate cancer. Clin Cancer Res 2007;13:1493-502.
54. Lim S, Lee C, Shin J-S, et al. Tumour infiltrating lymphocytes as a predictive and prognostic biomarker in rectal cancers treated with neoadjuvant chemoradiotherapy. Asia Pac J Clin Oncol 2013;9:58.
55. Kuremsky JG, Tepper JE, McLeod HL. Biomarkers for response to neoadjuvant chemoradiation for rectal cancer. Int J Radiat Oncol Biol Phys 2009;74:673-88.
56. Ghadimi BM, Grade M, Difilippantonio MJ, et al. Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy. J Clin Oncol 2005;23:1826-38.
57. Watanabe T, Komuro Y, Kiyomatsu T, et al. Prediction of sensitivity of rectal cancer cells in response to preoperative radiotherapy by DNA microarray analysis of gene expression profiles. Cancer Res 2006;66:3370-4.
58. Kim I-J, Lim S-B, Kang HC, et al. Microarray gene expression profiling for predicting complete response to preoperative chemoradiotherapy in patients with advanced rectal cancer. Dis Col Rect 2007;50:1342-53.
59. West CM, McKay MJ, Hölscher T, et al. Molecular markers predicting radiotherapy response: report and recommendations from an International Atomic Energy Agency technical meeting. Int J Radiat Oncol Biol Phys 2005;62:1264-73.
60. Popat S, Hubner R, Houlston R. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005;23:609-18.
61. Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda guidelines for Hereditary Nonpolyposis Colorectal Cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004;96:261-8.
62. Haydon AMM, Jass JR. Emerging pathways in colorectal-cancer development. Lancet Oncol 2002;3:83-8.
63. de la Chapelle A. Microsatellite Instability. New Engl J Med 2003;349:209-10.
64. Walther A, Johnstone E, Swanton C, et al. Genetic prognostic and predictive markers in colorectal cancer. Nature Rev Cancer 2009;9:489-99.
65. Kunkel TA, Erie DA. DNA mismatch repair. Ann Rev Biochem 2005;74:681-710.
66. Ham MF, Takakuwa T, Luo W-J, et al. Impairment of double-strand breaks repair and aberrant splicing of ATM and MRE11 in leukemia-lymphoma cell lines with microsatellite instability. Cancer Sci 2006;97:226-34.
67. Giannini G, Rinaldi C, Ristori E, et al. Mutations of an intronic repeat induce impaired MRE11 expression in primary human cancer with microsatellite instability. Oncogene 2004;23:2640-7.
68. Miquel C, Jacob S, Grandjouan S, et al. Frequent alteration of DNA damage signalling and repair pathways in human colorectal cancers with microsatellite instability. Oncogene 2007;26:5919-26.
69. Zhang Y, Rohde L, Emami K, et al. Suppressed expression of non-DSB repair genes inhibits gamma-radiation-induced cytogenetic repair and cell cycle arrest. DNA Repair 2008;7:1835-45.
70. Zhang Y, Rohde L, Wu H. Involvement of nucleotide excision and mismatch repair mechanisms in double strand break repair. Curr Genom 2009;10:250-8.
71. Chen J, Sadowski I. Identification of the mismatch repair genes PMS2 and MLH1 as p53 target genes by using serial analysis of binding elements. Proc Natl Acad Sci USA 2005;102:4813-18.
72. Franchitto A, Pichierri P, Piergentili R, et al. The mammalian mismatch repair protein MSH2 is required for correct MRE11 and RAD51 relocalization and for efficient cell cycle arrest induced by ionizing radiation in G2 phase. Oncogene 2003;22:2110-20.
73. Du C, Zhao J, Xue W, et al. Prognostic value of microsatellite instability in sporadic locally advanced rectal cancer following neoadjuvant radiotherapy. Histopathology 2013;62:723-30.
74. Smith F, Reynolds J, Miller N, et al. Pathological and molecular predictors of the response of rectal cancer to neoadjuvant radiochemotherapy. Eur J Surg Onc 2006;32:55-64.
75. Lochhead P, Kuchiba A, Imamura Y, et al. Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. J Natl Cancer Inst 2013;105:1151-6.
76. Umar A, Risinger J, Hawk E, et al. Testing guidelines for hereditary non-polyposis colorectal cancer. Nature Rev Cancer 2004;4:153-8.
77. Vasen HFA, Möslein G, Alonso A, et al. Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer). J Med Genet 2007;44:353-62.